See All Slides - tctmd.com

Slides

Presentation TCT 2013

On the PROSPECT of Reconciling COURAGE and FAME

Presenter: Jagat Narula

October 30, 2013

Presentation TCT 2013

Case #1: TAVR in a Patient with Mechanical Mitral Prosthesis: An Unexpected, Severe Complication

Presenter: Paolo Danna

October 30, 2013

Presentation TCT 2013

Case Presentation Conclusion: Procedural and Patient Outcomes(2)

Presenter: Michael Mullen

October 30, 2013

Presentation TCT 2013

Guideline Strategies for Antithrombotic Therapy in ACS: Contrasting the European and US Perspectives

Presenter: Philippe Gabriel Steg

October 30, 2013

Presentation TCT 2013

For Left Atrial Appendage Occlusion

Presenter: Brian Whisenant

October 30, 2013

Presentation TCT 2013

Introducing the Case(4)

Presenter: Feng-Yu Kuo

October 30, 2013

Presentation TCT 2013

Case presentation: Low Flow, Low Gradient Severe AS

Presenter: Ricardo Allende

October 30, 2013

Presentation TCT 2013

Keynote Address: The Intersection of Innovation, Payment and Regulatory Approval in the Future of Interventional Cardiology

Presenter: Jack Lewin

October 30, 2013

Presentation TCT 2013

Rationale for Bioresorbable Vascular Scaffolds as a VP Shield: The PROSPECT ABSORB Trial

Presenter: Gregg Stone

October 30, 2013

Presentation TCT 2013

Clinical Trial Alternatives for New LAA Occlusion Devices: For High-Risk AF Patients Who Are Tolerant to Anticoagulation or Poor Anticoagulation Candidates Due to Bleeding Risks...

Presenter: Brian Whisenant

October 30, 2013

Advertisement

Slides

On the PROSPECT of Reconciling COURAGE and FAME

Case #1: TAVR in a Patient with Mechanical Mitral Prosthesis: An Unexpected, Severe Complication

Case Presentation Conclusion: Procedural and Patient Outcomes(2)

Guideline Strategies for Antithrombotic Therapy in ACS: Contrasting the European and US Perspectives

For Left Atrial Appendage Occlusion

Introducing the Case(4)

Case presentation: Low Flow, Low Gradient Severe AS

Keynote Address: The Intersection of Innovation, Payment and Regulatory Approval in the Future of Interventional Cardiology

Rationale for Bioresorbable Vascular Scaffolds as a VP Shield: The PROSPECT ABSORB Trial

Clinical Trial Alternatives for New LAA Occlusion Devices: For High-Risk AF Patients Who Are Tolerant to Anticoagulation or Poor Anticoagulation Candidates Due to Bleeding Risks...

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content